Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corp (BCPC) delivers specialty performance ingredients for nutrition and industrial markets through advanced technologies. This news hub provides investors and industry professionals with essential updates on corporate developments and market leadership.
Access authoritative reporting on earnings announcements, product innovations, and strategic partnerships. Our curated collection ensures you stay informed about BCPC's advancements in microencapsulation techniques and chelation technology across human/animal nutrition sectors.
Discover press releases detailing regulatory milestones, manufacturing expansions, and sustainability initiatives. All content is verified for accuracy, offering neutral analysis without speculative commentary.
Bookmark this page for real-time access to Balchem's financial disclosures and operational updates. Regularly refreshed content supports informed decision-making for stakeholders tracking specialty chemical markets.
Balchem Corporation (NASDAQ: BCPC) reported a strong fourth quarter for 2021, achieving net earnings of $24.9 million, up 12.6% from $22.2 million in Q4 2020. Record net sales reached $213.1 million, reflecting a 17.9% increase year-over-year. For the full year, net earnings totaled $96.1 million, up 13.6% from 2020. The adjusted EBITDA for Q4 was $45.6 million, representing a 4.7% increase. The company's segments—Human Nutrition, Animal Nutrition, and Specialty Products—all recorded sales growth. A dividend of $0.64 per share signifies stable financial management.
Balchem Corporation (NASDAQ: BCPC) will host a conference call on February 18, 2022, at 11:00 AM ET to discuss its fourth-quarter results. The financial results will be published prior to the market opening on the same day. Interested parties can access the call by dialing toll-free 1-877-407-8289 or local 1-201-689-8341, five minutes before the start. A replay will be available after the call until March 4, 2022. Balchem operates in three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, focusing on enhancing health and well-being through specialized ingredients.
Alithya Group (NASDAQ: ALYA) continues its partnership with Balchem Corporation (NASDAQ: BCPC) to implement Microsoft Dynamics 365 across multiple global locations. This initiative, ongoing since 2017, aims to consolidate Balchem's operations and enhance financial visibility. The implementation spans over 20 plants in four countries, transitioning from multiple ERP systems. Balchem, a leader in nutrition and health solutions, emphasizes the importance of this digital transformation for supporting growth and operational efficiency.
Cornell University's recent research indicates that doubling the recommended prenatal choline intake significantly enhances childhood cognitive performance. The study, published in The FASEB Journal, found that children whose mothers consumed over 930 mg of choline during pregnancy showed enduring cognitive benefits by age seven. This research supports earlier findings from 2018 that linked higher maternal choline intake to improved infant cognition. The implications of this study may influence public health policies and encourage prenatal vitamin manufacturers to increase choline levels in their products.
Balchem Corporation (NASDAQ: BCPC) will be represented by CEO Ted Harris and CFO Martin Bengtsson at the CJS Securities 22nd Annual New Ideas for the New Year Conference on January 12, 2022. The company focuses on developing specialty ingredients that enhance health and well-being globally. Balchem operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, providing solutions for food, supplements, pharmaceuticals, and agricultural markets.
On January 10, 2022, Balchem Corporation (NASDAQ: BCPC) will be represented by CEO Ted Harris and CFO Martin Bengtsson at the H.C. Wainwright BIOCONNECT Virtual Conference. Balchem specializes in developing and marketing innovative ingredients aimed at enhancing health across various sectors. Their operations are categorized into three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, providing solutions for the food, supplement, pharmaceutical, and agricultural industries.
Balchem Corporation (NASDAQ: BCPC) has declared a dividend of $0.64 per share, marking a 10.3% increase from the previous year. This dividend will be payable on January 21, 2022, to stockholders of record by December 28, 2021. CEO Ted Harris highlighted this as the thirteenth consecutive increase in dividends, showcasing the company's strong financial performance and the Board’s confidence in its long-term strategies. Balchem is known for its specialty ingredients that enhance health across various industries.
Balchem Corporation (NASDAQ: BCPC) will participate in the Virtual Stephens Annual Investment Conference on November 29, 2021. The company's leadership, including CEO Ted Harris and CFO Martin Bengtsson, will represent Balchem at this significant investment event. Balchem specializes in developing and marketing specialty ingredients, categorized into three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Their offerings enhance health across various industries, including food, supplements, and pharmaceuticals.
Balchem Corporation (NASDAQ: BCPC) will be represented by its Chairman and CEO, Ted Harris, and CFO, Martin Bengtsson, at the Baird 2021 Global Industrial Conference on November 10, 2021. The presentation will be accessible on Balchem's investor relations website after the event. Balchem specializes in developing and marketing ingredients that enhance health and well-being across various industries, with three main segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
FAQ
What is the current stock price of Balchem (BCPC)?
What is the market cap of Balchem (BCPC)?
